Jim Cramer has expressed his disappointment with the performance of Royalty Pharma stock due to its recent 52-week lows. However, recommendations to hold the stock indicate a belief in its long-term potential as a defensive asset. With Q3 reporting a solid 15% revenue growth and $1.2B in deployment, driving guidance up, Royalty Pharma maintains Strong-Buy ratings by TD Cowen amid high trading volumes and increases in stake by Barclays PLC and Franklin Resources Inc. Furthermore, it has secured a $125M RYTELO deal and a strategic $350 million royalty funding agreement for Niktimvo™ with Syndax Pharmaceuticals, demonstrating active capital utilization.
However, some bearish signals have been flagged due to insiders disposing stocks and the financials bring ambiguity in terms of future performance. Major milestones include FDA approval and an expansion of its portfolio through partnerships and strategic investments, including a share of Cytokinetics' heart drug and backing a financing deal for Geron Corp's RYTELO launch. Combining these factors, there remains a massive opportunity for Royalty despite current market shifts.
Royalty Pharma Stocks News Analytics from Sat, 08 Jul 2017 07:00:00 GMT to Fri, 27 Dec 2024 08:00:00 GMT - Rating -3 - Innovation 1 - Information 7 - Rumor -5
